Brief: Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
20/05/2025 13:18
May 20 (Reuters) - Marker Therapeutics Inc MRKR.O: MARKER THERAPEUTICS REPORTS THAT LYMPHODEPLETION IMPROVES THE EXPANSION AND PERSISTENCE OF MULTI-ANTIGEN RECOGNIZING T CELLS IN PATIENTS WITH LYMPHOMA Source text: ID:nGNX5q2KmX Further company coverage: MRKR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79